A study of the safety and immunogenicity of two different recombinant DNA yeast-derived hepatitis B vaccines was conducted in 90 young adults according to a 0-, 1-, and 6-month vaccination schedule. Preliminary results using the 20 μg SmithKline Biologicals or 10 μg Merck Sharp & Dohme recombinant yeast-derived hepatitis B vaccines indicate that both vaccines are clinically safe and immunogenic. Only minor side effects have thus far been reported. Seroconversion rates among vaccine recipients were 80% or greater after the first two injections with either vaccine, and 100% after the third dose of the SmithKline Biologicals recombinant DNA hepatitis B vaccine.
|Titolo:||Immunogenicity of yeast-derived hepatitis B vaccines in young adults|
BERGAMINI, FERNANDA (Primo)
ZANETTI, ALESSANDRO REMO (Ultimo)
|Settore Scientifico Disciplinare:||Settore MED/42 - Igiene Generale e Applicata|
|Data di pubblicazione:||1987|
|Appare nelle tipologie:||01 - Articolo su periodico|